← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

ImmunityBio, Inc. (IBRX) 10-Year Financial Performance & Capital Metrics

IBRX •
HealthcareBiotechnologyOncology Therapeutics Developers
AboutImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.Show more
  • Revenue $15M +2270.6%
  • EBITDA -$327M +5.0%
  • Net Income -$414M +29.1%
  • EPS (Diluted) -0.62 +46.1%
  • Gross Margin 100%
  • EBITDA Margin -2215.18% +96.0%
  • Operating Margin -2334.23% +96.0%
  • Net Margin -2804.77% +97.0%
  • ROE -
  • ROIC -
  • Debt/Equity -
  • Interest Coverage -2.61 +37.4%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 98 (top 2%)
  • ✓Strong 5Y sales CAGR of 221.4%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 37.7% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y36.83%
5Y221.39%
3Y150.86%
TTM1025.95%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM40.69%

EPS CAGR

10Y-
5Y-
3Y-
TTM55.33%

ROCE

10Y Avg-116.2%
5Y Avg-175.11%
3Y Avg-153.18%
Latest-88.92%

Peer Comparison

Oncology Therapeutics Developers
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
EXELExelixis, Inc.11.81B44.0615.856.98%29.63%31.37%7.49%0.08
INCYIncyte Corporation20.1B101.2715.8021.22%25.03%24.9%6.74%0.01
GMABGenmab A/S18.13B29.4415.3630.67%46.8%114.25%6.6%0.03
SNDXSyndax Pharmaceuticals, Inc.1.89B21.71-5.82-279.31%-269.93%1.20
RCUSArcus Biosciences, Inc.2.55B20.37-6.19-4.26%-142.91%-55.94%0.16
RLAYRelay Therapeutics, Inc.1.78B10.26-6.3753.44%-18.01%-48.76%0.06
STROSutro Biopharma, Inc.1.74B20.47-6.92-59.64%-205.18%-234.19%4.57
OLMAOlema Pharmaceuticals, Inc.1.66B24.20-11-48.77%0.00

Compare IBRX vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs RVMD

Compare head-to-head with Revolution Medicines, Inc.

vs INCY

Compare head-to-head with Incyte Corporation

Compare Top 5

vs RVMD, INCY, GMAB, EXEL

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+236K44K45K47K43K605K934K240K622K14.74M
Revenue Growth %-63.18%-81.36%2.27%4.44%-8.51%1306.98%54.38%-74.3%159.17%2270.58%
Cost of Goods Sold+000-3.11M9.01M00000
COGS % of Revenue----6617.02%20958.14%-----
Gross Profit+236K44K45K3.16M-8.97M605K934K240K622K14.74M
Gross Margin %100%100%100%6717.02%-20858.14%100%100%100%100%100%
Gross Profit Growth %-63.18%-81.36%2.27%6915.56%-384.1%106.75%54.38%-74.3%159.17%2270.58%
Operating Expenses+237.64M120.94M93.6M88.88M57.94M221.49M331.21M351.54M362.87M358.93M
OpEx % of Revenue100694.92%274856.82%207997.78%189108.51%134739.53%36609.09%35461.88%146474.17%58339.55%2434.23%
Selling, General & Admin226.21M94.39M53.82M35.46M9.05M71.32M135.26M102.71M129.62M168.78M
SG&A % of Revenue95850%214525%119602.22%75453.19%21053.49%11788.1%14481.37%42795%20839.23%1144.68%
Research & Development11.43M26.55M39.78M53.42M48.88M139.51M195.96M248.15M232.37M190.14M
R&D % of Revenue4844.92%60331.82%88395.56%113655.32%113686.05%23059.01%20980.51%103395.42%37357.88%1289.55%
Other Operating Expenses0000010.66M0681K886K0
Operating Income+-238.88M-124.5M-99.12M-98.39M-66.91M-220.88M-330.28M-351.3M-362.25M-344.18M
Operating Margin %-101218.64%-282954.55%-220266.67%-209338.3%-155597.67%-36509.09%-35361.88%-146374.17%-58239.55%-2334.23%
Operating Income Growth %-3745.4%47.88%20.39%0.74%32%-230.13%-49.53%-6.36%-3.12%4.99%
EBITDA+-237.4M-120.89M-93.55M-88.83M-57.9M-208.14M-316.04M-333.04M-343.74M-326.63M
EBITDA Margin %-100594.92%-274756.82%-207897.78%-189008.51%-134639.53%-34403.47%-33837.47%-138765.83%-55263.34%-2215.18%
EBITDA Growth %-3802.1%49.08%22.61%5.05%34.83%-259.51%-51.84%-5.38%-3.21%4.98%
D&A (Non-Cash Add-back)1.47M3.61M5.57M9.55M9.01M12.74M14.24M18.26M18.51M17.55M
EBIT-237.18M-121.31M-96.3M-96.3M-65.87M-216.96M-334.99M-370.14M-497.18M-281.99M
Net Interest Income+0000-3.16M-7.35M-14.01M-44.44M-85.85M-129.26M
Interest Income00002.76M1.73M836K2.71M863K2.4M
Interest Expense066K618K433K5.92M9.07M14.85M47.15M86.72M131.66M
Other Income/Expense1.7M3.12M2.2M1.66M1.02M-5.15M-19.56M-65.99M-221.64M-69.46M
Pretax Income+-237.18M-121.38M-96.92M-96.73M-65.89M-226.03M-349.84M-417.29M-583.89M-413.64M
Pretax Margin %-100498.73%-275865.91%-215368.89%-205806.38%-153223.25%-37360.83%-37456%-173869.17%-93873.31%-2805.32%
Income Tax+-301K-572K-493K-503K-97K-1.85M9K34K-40K0
Effective Tax Rate %99.87%99.53%99.49%99.48%99.85%98.15%99.13%99.83%99.88%99.98%
Net Income+-236.88M-120.81M-96.42M-96.23M-65.79M-221.85M-346.79M-416.57M-583.2M-413.56M
Net Margin %-100371.19%-274565.91%-214273.33%-204736.17%-152997.67%-36669.59%-37129.55%-173569.58%-93761.41%-2804.77%
Net Income Growth %-3712.59%49%20.19%0.2%31.63%-237.22%-56.32%-20.12%-40%29.09%
Net Income (Continuing)-236.88M-120.81M-96.42M-96.23M-65.79M-224.19M-349.85M-417.32M-583.85M-413.64M
Discontinued Operations0000000000
Minority Interest000-12.32M01.32M-1.74M-2.49M1.05M969K
EPS (Diluted)+-0.73-0.37-0.30-0.30-0.42-0.59-0.89-1.04-1.15-0.62
EPS Growth %-3605.58%49.32%18.92%0%-40%-40.48%-50.85%-16.85%-10.58%46.09%
EPS (Basic)-0.73-0.37-0.30-0.30-0.42-0.59-0.89-1.04-1.15-0.59
Diluted Shares Outstanding326.3M328.55M316.15M325.05M383.18M383.18M389.23M399.9M508.64M700.44M
Basic Shares Outstanding326.3M328.55M316.15M325.05M383.18M383.18M389.23M399.9M508.64M697.31M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+297.54M205.15M132.46M88.77M55.76M111.71M334.35M140.58M294.08M184.59M
Cash & Short-Term Investments294.22M198.92M128.15M74.15M51.65M96.06M317.12M107.18M266.46M149.81M
Cash Only175.91M8.08M23.87M16.82M15.51M34.91M181.1M104.64M265.45M143.43M
Short-Term Investments118.31M190.84M104.28M57.33M36.14M61.15M136.01M2.54M1.01M6.38M
Accounts Receivable1.77M01.26M12.17M303K2M1.33M1.89M3.17M2.65M
Days Sales Outstanding2.74K-10.2K94.5K2.57K1.21K520.932.87K1.86K65.67
Inventory0000000008.27M
Days Inventory Outstanding----------
Other Current Assets0662K880K42K24K02.96M2.9M5.21M1.3M
Total Non-Current Assets+69.31M112.35M117.98M93.18M87.37M109.67M134.56M221.78M210.37M198.35M
Property, Plant & Equipment6.15M19.27M76.73M76.89M72.23M90.68M119.17M189.45M182.68M170.46M
Fixed Asset Turnover0.04x0.00x0.00x0.00x0.00x0.01x0.01x0.00x0.00x0.09x
Goodwill0000000000
Intangible Assets7.29M5.09M2.83M12.09M01.46M1.42M20M17.09M15.93M
Long-Term Investments55.13M87.75M38.28M14.38M10.93M11.4M7.6M840K891K0
Other Non-Current Assets344K137K151K-1.67M4.21M6.13M6.38M11.49M9.7M11.96M
Total Assets+366.85M317.5M250.44M181.95M143.12M221.38M468.91M362.36M504.45M382.93M
Asset Turnover0.00x0.00x0.00x0.00x0.00x0.00x0.00x0.00x0.00x0.04x
Asset Growth %503.09%-13.45%-21.12%-27.35%-21.34%54.68%111.81%-22.72%39.21%-24.09%
Total Current Liabilities+6.15M12.55M20.87M27.26M11.56M68.13M369M500.86M58.28M54.94M
Accounts Payable2.08M4.04M5.87M2.79M1.75M11.51M11.42M21.02M9.2M6.72M
Days Payables Outstanding----327.870.84-----
Short-Term Debt-228K534K618K965K3.96M0299.24M431.9M00
Deferred Revenue (Current)228K197K520K0000000
Other Current Liabilities4.06M7.78M13.87M23.5M4.78M18M16.52M19.74M18.31M15.98M
Current Ratio48.40x16.34x6.35x3.26x4.82x1.64x0.91x0.28x5.05x3.36x
Quick Ratio48.40x16.34x6.35x3.26x4.82x1.64x0.91x0.28x5.05x3.21x
Cash Conversion Cycle----------
Total Non-Current Liabilities+4.71M11.53M10.73M8.68M10.88M271.74M343.83M311.31M1.03B816.12M
Long-Term Debt2.47M0000254.35M306.35M241.27M681.54M461.88M
Capital Lease Obligations2.47M7.68M6.65M5.95M10.88M16.18M37.07M47.95M39.94M34.82M
Deferred Tax Liabilities1.17M996K498K00170K162K000
Other Non-Current Liabilities-1.4M2.67M3.41M2.74M01.03M249K22.09M310.63M319.42M
Total Liabilities10.85M24.08M31.6M35.94M22.44M339.87M712.82M812.18M1.09B871.06M
Total Debt+2.47M8.21M7.27M6.91M14.85M275.55M645.66M723.77M726.72M504.17M
Net Debt-173.44M127K-16.6M-9.91M-660K240.63M464.56M619.13M461.27M360.74M
Debt / Equity0.01x0.03x0.03x0.05x0.12x-----
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage--1886.36x-160.39x-227.23x-11.30x-24.34x-22.24x-7.45x-4.18x-2.61x
Total Equity+356M293.42M218.84M133.69M120.68M-118.49M-243.91M-449.82M-585.94M-488.13M
Equity Growth %509.34%-17.58%-25.42%-38.91%-9.73%-198.19%-105.85%-84.42%-30.26%16.69%
Book Value per Share1.090.890.690.410.31-0.31-0.63-1.12-1.15-0.70
Total Shareholders' Equity356M293.42M218.84M146.01M120.68M-119.81M-242.17M-447.33M-586.99M-489.1M
Common Stock8K8K8K8K10K38K40K42K67K85K
Retained Earnings-250.38M-387.06M-498.71M-594.98M-662.19M-1.62B-1.96B-2.38B-2.96B-3.38B
Treasury Stock0000000000
Accumulated OCI-192K-284K-381K-267K-105K122K4K183K10K1.2M
Minority Interest000-12.32M01.32M-1.74M-2.49M1.05M969K

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-25.3M-38.59M-48.78M-63.38M-152.11M-171.72M-274.42M-337.51M-366.76M-391.24M
Operating CF Margin %-10722.46%-87711.36%-108400%-134853.19%-353741.86%-28384.13%-29381.05%-140628.75%-58964.15%-2653.35%
Operating CF Growth %-372.64%-52.51%-26.4%-29.93%-139.99%-12.9%-59.8%-22.99%-8.67%-6.67%
Net Income-236.88M-120.81M-96.42M-96.23M-160.16M-224.19M-346.79M-416.57M-583.85M-413.64M
Depreciation & Amortization1.47M3.61M5.57M9.55M14.04M12.74M14.3M34.54M18.51M17.55M
Stock-Based Compensation211.22M73.85M37M2.04M3.42M2.19M57.18M40.18M49.16M34.43M
Deferred Taxes-302K-575K-497K-498K-8K-2.94M0000
Other Non-Cash Items212.36M81.67M50.33M44.55M6.23M24.11M16.29M20.34M145.44M-10.15M
Working Capital Changes282K3.84M3.23M-554K-15.64M16.36M-15.39M-16M3.98M-19.42M
Change in Receivables75K-1.46M0000000-2.36M
Change in Inventory000000000-8.27M
Change in Payables627K888K150K-1.1M1.19M2.57M00-6.48M-3.17M
Cash from Investing+-175.22M-113.67M99.55M57.1M18.55M-19.81M-84.89M27.3M-30.47M-12.25M
Capital Expenditures-2.24M-6.56M-34.81M-13.1M-4.29M-1.67M-33.56M-78.16M-30.58M-6.89M
CapEx % of Revenue949.58%14909.09%77366.67%27876.6%9969.77%275.87%3593.47%32567.5%4917.04%46.71%
Acquisitions-1.82M-137K-32K412K200K8K000-1M
Investments----------
Other Investing-1.82M137K32K35.03M-2.5M-8K-51.32M105.46M0-747K
Cash from Financing+317.33M-15.56M-34.98M-771K114.28M150.68M505.44M233.61M558.34M281.63M
Debt Issued (Net)-132K-32K-19.93M-477K47.67M63.7M338.5M174.07M258.62M96.89M
Equity Issued (Net)1000K-1000K-1000K-171K1000K1000K-1000K-616K1000K1000K
Dividends Paid0000000000
Share Repurchases-4.8M-15.85M-15.23M-228K-2.5M0-4.06M-616K00
Other Financing-2.42M-1.11M-1.04M-123K39.11M673K171.01M60.16M189.62M73.38M
Net Change in Cash116.8M-167.82M15.79M-7.05M-19.3M-40.89M146.19M-76.31M160.82M-121.88M
Free Cash Flow+-27.55M-45.15M-83.59M-76.48M-156.4M-173.39M-307.98M-415.67M-397.34M-398.12M
FCF Margin %-11672.03%-102620.45%-185766.67%-162729.79%-363711.63%-28660%-32974.52%-173196.25%-63881.19%-2700.06%
FCF Growth %-387.28%-63.92%-85.14%8.51%-104.48%-10.87%-77.62%-34.97%4.41%-0.2%
FCF per Share-0.08-0.14-0.26-0.24-0.41-0.45-0.79-1.04-0.78-0.57
FCF Conversion (FCF/Net Income)0.11x0.32x0.51x0.66x2.31x0.77x0.79x0.81x0.63x0.95x
Interest Paid000019K40K2.11M35.44M77.19M92.32M
Taxes Paid00003K8K008K15K

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-114.32%-37.21%-37.65%-54.59%-51.73%-20269.62%----
Return on Invested Capital (ROIC)-196.73%-39.23%-29.99%-45.27%-41.17%-136.82%-144.53%-135.13%-1217.1%-
Gross Margin100%100%100%6717.02%-20858.14%100%100%100%100%100%
Net Margin-100371.19%-274565.91%-214273.33%-204736.17%-152997.67%-36669.59%-37129.55%-173569.58%-93761.41%-2804.77%
Debt / Equity0.01x0.03x0.03x0.05x0.12x-----
Interest Coverage--1886.36x-160.39x-227.23x-11.30x-24.34x-22.24x-7.45x-4.18x-2.61x
FCF Conversion0.11x0.32x0.51x0.66x2.31x0.77x0.79x0.81x0.63x0.95x
Revenue Growth-63.18%-81.36%2.27%4.44%-8.51%1306.98%54.38%-74.3%159.17%2270.58%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.